Tocilizumab — Drug Intelligence | 120 EU Trials

Filter these 120 trials by condition, phase, country and more.

Open in Search →

120 Registered trials

49 Recruiting

50 Completed trials

60 Sponsors

26 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 31 Phase II: 40 Phase I/II: 26 Phase III/IV: 1 Phase IV: 8 Phase I: 1 Phase I (FiH): 13

Oversight events:

5 serious breaches 30 temporary halts 4 urgent safety measures 20 unexpected events 9 corrective measures across 26 trials

View oversight register →

Indications tested

Follicular lymphoma 6 B-cell lymphoma refractory 4 Diffuse large B-cell lymphoma 3 Lupus nephritis 3 Diffuse large B-cell lymphoma recurrent 3 Juvenile idiopathic arthritis 3 Systemic lupus erythematosus 3 B-cell lymphoma recurrent 3 Primary mediastinal large B-cell lymphoma 2 Rheumatoid arthritis 2 Diffuse large B-cell lymphoma refractory 2 High-grade B-cell lymphoma 2

Sponsors using this IMP

F. Hoffmann-La Roche AG 15 Novartis Pharma AG 13 Assistance Publique Hopitaux De Paris 9 Genmab A/S 5 AstraZeneca AB 4 Regeneron Pharmaceuticals Inc. 4 Amgen Inc. 3 Celgene Corp. 3 Kite Pharma Inc. 3 Miltenyi Biomedicine GmbH 3 AbbVie Deutschland GmbH & Co. KG 2 Allogene Therapeutics Inc. 2

All trials — page 4

120 total

Effect of different drugs on the immune response during inflammation: the DEDICATE-LPS study Ended

2023-506556-24-00 Phase II 1 country Stichting Radboud University Medical Center
Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to expre… Ended

2024-515467-66-00 Phase II 1 country Fundacio Sant Joan De Deu
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
TocilizuMab discontinuAtion in GIant Cell Arteritis Ended

2023-505515-21-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended

2023-503452-27-00 Phase III 7 countries Novartis Pharma AG
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Phase III 15 countries Amgen Inc.
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended

2022-501346-30-00 Phase III 12 countries Celgene Corp.
An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended

2023-510081-27-00 Phase I/II 3 countries Novartis Pharma AG
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 Phase II 8 countries Genmab A/S
A Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multi… Ended

2023-505865-94-00 Phase I/II 5 countries F. Hoffmann-La Roche AG
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
DALY 2-EU Ended

2023-506270-13-00 Phase II 15 countries Miltenyi Biomedicine GmbH
A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination w… Ended

2023-506899-27-00 Phase III 6 countries F. Hoffmann-La Roche AG
Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-conce… Ended

2023-509458-77-00 Phase II 1 country Amsterdam UMC
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 Phase III 13 countries Genmab A/S
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Phase I/II 10 countries Genmab A/S
Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended

2023-507062-34-00 Phase I (FiH) 5 countries Novartis Pharma AG
A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i… Ended

2023-507236-20-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
A study to look at how safe and effective glofitamab plus R-CHOP in ctDNA high-risk people with untreated diffuse large B-cell lymphoma Ended

2023-504994-19-00 Phase II 5 countries F. Hoffmann-La Roche AG
MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended

2024-512269-14-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l… Ended

2022-502616-37-00 Phase I/II 5 countries F. Hoffmann-La Roche AG
A prospective controlled trial to evaluate safety and efficacy of in vitro expanded recipient regulatory T cell therapy and tocilizumab toge… Ended

2024-513459-34-00 Phase I/II 1 country Medical University Of Vienna
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
Talquetamab (GPRC5D and CD3 antibody) in Relapsed or Refractory Multiple Myeloma Ended

2023-504581-29-00 Phase I (FiH) 6 countries Janssen - Cilag International

Showing 73–96 of 120 trials

← All drugs A–Z